TNF- inhibitors Infliximab Infliximab is a recombinant chimeric monoclonal antibody that effectively inhibits the binding of tumor necrosis TNF- to both its soluble and transmembrane receptors [355]
Canada Europe Germany France UK Italy Spain Netherlands Russia Rest of Europe Asia Pacific China Japan India Malaysia South Korea Indonesia Australia Vietnam Rest of Asia Pacific Middle East & Africa Saudi Arabia UAE Israel South Africa Rest of Middle East & Africa Latin America Mexico Brazil Argentina Rest of Latin America GLP-1 Market Report Scope Source: Polaris Market Research Analysis GLP-1 Market FAQ's The GLP-1 market was valued at USD 52.82 billion in 2025 and is projected to reach USD 133.92 billion by 2034
Link Centers for Disease Control and Prevention, About Obesity
Yaribeygi, H., Jamialahmadi, T., Moallem, S.A., Sahebkar, A
Right ventricular stiffening and anisotropy alterations in pulmonary hypertension: mechanisms and relations to right heart failure
Alteration of sweet taste in high-fat diet induced obese rats after 4 weeks treatment with exenatide
